Biogen U.s. Corporation
Cambridge, MA
- UEI
- E82LHNZSCUA3
- CAGE
- 6M2Q6
- Primary NAICS
- 325412 Pharmaceutical Preparation Manufacturing
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 225 Binney St, Cambridge, MA 02142, USA
- Website
- biogen.com
- Founded
- 1978
- Employees
- 5K-10K
- Estimated annual revenue
- $10B+
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | $0 |
| FY2025 | $43,477 |
| FY2024 | $163,037 |
Contract vehicles
Contract awards
Latest 5 listed here. See the rest on GovTribe.
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Mirum Pharmaceuticals, Inc. | San Mateo, CA | 325412 Pharmaceutical Preparation Manufacturing |
| Avadel CNS Pharmaceuticals, LLC | Chesterfield, MO | 325412 Pharmaceutical Preparation Manufacturing |
| Acer Therapeutics Inc. | Boston, MA | 456110 Pharmacies and Drug Retailers |
| Amylyx Pharmaceuticals Inc. | — | 424210 Drugs and Druggists' Sundries Merchant Wholesalers |
| U.s. Division | Rockville, MD | 424210 Drugs and Druggists' Sundries Merchant Wholesalers |
About the company
Biogen U.s. Corporation is a pharmaceutical and biotechnology company registered in the System for Award Management (SAM) since December 16, 2011, with a corporate structure as a for-profit organization and manufacturer of goods. The company specializes in developing and supplying pharmaceutical products, with a particular focus on neurological disease therapies. Its federal contract portfolio demonstrates expertise in providing specialized pharmaceutical products to federal agencies, primarily within the healthcare sector.
Through its federal contract awards, Biogen U.s. Corporation has predominantly supplied pharmaceutical products to the Department of Veterans Affairs (VA), specifically through the VA's Veterans Integrated Service Networks (VISN) 20 and 21. The company has been awarded multiple delivery orders for QALSODY (tofersen), a pharmaceutical product used to treat neurological conditions, with contract values ranging from $10,869.15 to $43,476.60. These delivery orders were placed against the company's Pharmaceuticals and Drugs General Services Administration (GSA) Schedule contract, and notably, none of these awards were set aside for specific business types, indicating Biogen competed on the open market. All contracts were firm-fixed-price delivery orders, suggesting a standardized pricing model for pharmaceutical procurement.
Biogen U.s. Corporation holds two significant Indefinite Delivery Vehicles (IDVs) with the VA National Acquisition Center. The first is a single-award indefinite delivery contract valued at $11,392,063.40 for supplying ranibizumab ophthalmic injections to the VA, Bureau of Prisons, and Indian Health Service, with a performance period through December 22, 2025. The second IDV is a Blanket Purchase Agreement worth $430,578.10 for the drug Spinraza, used to treat spinal muscular atrophy, placed against the Pharmaceuticals and Drugs (FSS-61-IB) GSA Schedule. Both IDVs are single-award contracts without specific set-aside designations, enabling efficient pharmaceutical procurement for federal healthcare agencies through December 2025.
Quick answers
Is Biogen U.s. Corporation registered in SAM.gov?
Yes. Biogen U.s. Corporation's SAM.gov registration is active through June 2, 2027.
What is Biogen U.s. Corporation's CAGE code?
Biogen U.s. Corporation's CAGE code is 6M2Q6, and its Unique Entity ID (UEI) is E82LHNZSCUA3.
Which contract vehicles does Biogen U.s. Corporation hold?
Biogen U.s. Corporation holds a place on 1 federal contract vehicle: FSS-61-IB.
How much has Biogen U.s. Corporation received in federal contracts?
Federal contracts obligated $43,477 to Biogen U.s. Corporation in fiscal year 2025 and $206,514 in fiscal years 2023 through 2027.
What is Biogen U.s. Corporation's most recent federal award?
Biogen U.s. Corporation's most recent federal contract award is Qalsody bulk (36C26025F0084), from Veterans Integrated Service Network 20 (VHA), on November 13, 2024.
On GovTribe
See Biogen U.s. Corporation's full federal record
- Federal contract awards
- IDV awards
- Contract vehicles
- Funding analysis by agency, NAICS and set-aside
- Similar vendors